On the other hand, considering the correlation of PD‐L1 expression by tumor cells with the likelihood of response to anti‐PD‐1/PD‐L1 therapy, immune checkpoint inhibitors might be an active treatment option for unresectable or relapsed TCs. The gene discussed is CD274; the disease is neoplasm.